Online inquiry

IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9258MR)

This product GTTS-WQ9258MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CEACAM5 gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1048
UniProt ID P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9258MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12487MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ12049MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ6870MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DX-2930
GTTS-WQ15381MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ15949MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ1530MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ3131MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ8746MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuPRO-140
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW